Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity

Rapamycin, a specific inhibitor for mTOR complex 1, is an FDA-approved immunosuppressant for organ transplant. Recent developments have raised the prospect of using rapamycin to treat cancer or diabetes and to delay aging. It is therefore important to assess how rapamycin treatment affects glucose h...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shi-Bing, Lee, Hye Young, Young, David Matthew, Tien, An-Chi, Rowson-Baldwin, Ashley, Shu, Yu Yu, Jan, Yuh Nung, Jan, Lily Yeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3354320/
https://www.ncbi.nlm.nih.gov/pubmed/22105852
http://dx.doi.org/10.1007/s00109-011-0834-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3354320/
https://www.ncbi.nlm.nih.gov/pubmed/22105852
http://dx.doi.org/10.1007/s00109-011-0834-3

Ejemplares similares